Menu
Background An established, biomedical research facility was looking to enter into an agreement with a hospital organization which would absorb the research institute in exchange …
Background A pharmaceutical company, in the midst of a Phase III clinical trial, was considering a variety of strategic and financing alternatives as it prepared …
Over the past several years, Teknos has valued hundreds of types of cryptocurrencies and tokens (utility, security, stable, etc.) for a variety of purposes. Over …
Background While growth in Esports has been rapid over recent years, this growth can often result in the need for adjustments to overarching strategic initiatives …
Biotechnology companies face unique challenges when it comes to understanding the value of their assets. During the early stages of development, an extraordinary level of …
IRC 409A became part of the tax code on January 1, 2009. So, what have we learned in recent years*? One of the biggest surprises …
A number of Teknos client companies complete an IPO every year and we thought that it would be worthwhile to share the best practices that …
In the past, common stockholders had to wait for a company to complete an IPO or to be acquired in order to sell their shares. …
Your Investments and ASC 820
The financial reporting requirements of ASC 820 can be overwhelming for the finance teams of any venture capital firm. Fortunately, Teknos Associates provides a customized …